Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Dec
16
Today In Oncology
Flipped Nivolumab/Ipilimumab Dosing Improves Outcomes in Advanced Melanoma
Tanning Bed Exposure and Melanoma Risks
FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
HER2-Positive Breast Cancer FDA Approves T-DXd Plus Pertuzumab
Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo